Article Versions Notes

Siegel M, Steiner G, Franssen LC, Carratu F, Herron J, Hartman K, Looney CM, Ducret A, Bray-French K, Rohr O, et al. Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics. Pharmaceutics. 2022; 14(12):2672. https://doi.org/10.3390/pharmaceutics14122672

Siegel, Michel, Guido Steiner, Linnea C. Franssen, Francesca Carratu, James Herron, Katharina Hartman, Cary M. Looney, Axel Ducret, Katharine Bray-French, Olivier Rohr, and et al. 2022. "Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics" Pharmaceutics 14, no. 12: 2672. https://doi.org/10.3390/pharmaceutics14122672

Siegel, M., Steiner, G., Franssen, L. C., Carratu, F., Herron, J., Hartman, K., Looney, C. M., Ducret, A., Bray-French, K., Rohr, O., Hickling, T. P., Smith, N., & Marban-Doran, C. (2022). Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics. Pharmaceutics, 14(12), 2672. https://doi.org/10.3390/pharmaceutics14122672